a public good project by the
Synthesis
Company
of California

© 2026

Merete Lund Hetland | doi.page

0 works0 citations0 h-index

Merete Lund Hetland

University of Copenhagen(DK)Glostrup Hospital(DK)Rigshospitalet(DK)

Publications by Year

Research Areas

Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research, Monoclonal and Polyclonal Antibodies Research

Most-Cited Works

→ EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update(2020)2,709 cited
→ Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry(2009)537 cited
→ Health in Old Age: How Do Physicians' Ratings and Self-ratings Compare ?(1979)383 cited
→ MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)(2008)364 cited
→ FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries(2014)317 cited

→ EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis(2016)

305 cited

→ EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update(2024)283 cited

→ A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry(2017)247 cited

→ Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry(2010)244 cited

Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis.(2008)